Here is your chance to sign up for the hottest penny stock alerts. You won't want to miss out on this great opportunity!
Sign up by text message now & get ready to make HUGE GAINS.
(We are 100% Anti-Spam and will never rent or sell your information)
Allerayde SAB Inc (ASAB) has developed a comprehensive range of consumer healthcare products for the major and growing markets of allergy and eczema and is in the final stages of developing the worlds first truly generic epinephrine auto-injector (AAA Pen) for the self treatment of anaphylaxis (allergy shock). ASAB will introduce its products, in a rolling campaign, into the key markets of the USA, Canada, UK, France and Germany with the objective becoming the supplier of choice. ASAB is using the strategy of out sourcing to reduce unnecessary fixed costs and maximising returns. Focus will be on opening up channels of distribution and the logistics of the supply chain. A key role of the management team will be to utilise over 30 years of in house marketing expertise in professional and consumer allergy markets to generate success.
ASAB now has the opportunity to make significant sales in the allergy/eczema market, where revenue is well in excess of $40 billion, with epinephrine auto-injectors having over $750 million and both are growing. The availability of a generic epinephrine auto-injector will also open up previously untapped markets.
Allergy Market Asthma and allergic diseases account for a significant proportion of the chronic illnesses that a.ict human beings. Worldwide, asthma has been described as an epidemic that has increased both in prevalence and incidence over the last 20 years despite improved pharmacotherapy and environmental control. In the same way, allergic diseases such as rhinitis, food allergy, atopic dermatitis and asthma triggered by allergies have also increased. The total burden of these chronic diseases is staggering.
ASAB has spent the last 2 years developing its new products, and is ready to launch its range of allergen avoidance measures and its eczema garments. Our new epinephrine auto-injector, AAA Pen®, is in its final stages of development.
Recent estimates of the annual cost of asthma in the USA are nearly $18 billion per year; with direct costs (treatment) nearly $10 billion. In addition to asthma, it has been estimated that 1 in 5 Americans, or 50 million persons, experience allergies, including nasal allergies, food allergy, drug allergy, atopic eczema, and insect allergy. The incidence of allergic diseases has been increasing in all age groups for the past 20 years. The annual cost of such allergies in the USA is estimated to be nearly $7 billion.
Anaphylaxis a.ects up to 2.0% of the population at some point during their lifetime. Epinephrine auto-injectors are universally recommended for patients at risk for recurrent anaphylaxis; however, they are unavailable or too expensive in many countries and, in the few countries where they are available, they range in price from $54.50-$168.66.
Allerayde will use previous management experience in anaphylaxis, allergen avoidance and eczema to gain market share in the UK, Ireland, Germany, France, the USA and Canada. The strategy will be to approach three diverent segments, healthcare professionals, the patient population and B2B (including Amazon.com). Marketing tools will include product catalogues (for doctors o.ces and direct to patients, an updated website (including country specific e-shop), mail shots to clinicians, public relations, face to face calls with clinicians and B2B contacts and relevant exhibitions. It is the ambition of ASAB to achieve 40%+ market share with AAA Pen® and be in the top three suppliers within the consumer market in all of its target countries. This will be achieved firstly for product e.cacy reasons and secondly through value price advantage gained by utilizing modern manufacturing, assembly and distribution techniques. Specialist contract manufacturers in Europe have been selected, for all products, and the terms of manufacturing agreed. Supply contracts for both will be on an exclusive basis.
For morte info on Allerayde SAB, Inc - Symbol: ASAB please visit the website at - www.alleraydesab.com
These days email delivery is often not the best way to get an urgent alert. Fighting the spam traps is a daily battle. We now offer our alerts over the SMS text messaging system. Never miss another major alert. You can even sign up by simply texting the word ’stock’ to 46786. The service is free but normal text charges may apply according to your individual text plan.
Although making superb gains 100% of the time is an impossible promise for anyone to make, our track record speaks for itself. 11 out of our last 12 picks posted gains after we issued an alert to our members. Many of those went on to post over 1000% and even 2000% gains. Imagine what that could have meant for your bottom line?
Yes. Our service is 100% FREE If you choose our SMS Text Alert Service please remember that some cellphone service providers do charge text and data rates for each message recieved. Check with your provider to be sure.
Any serious player knows that timing is everything. If you miss an early run you miss an opportunity to make money. If you miss a sell alert you’re losing money. Our job is to get you the information you need when you need it. Be a winner. Be the first to know. Sign up today!
What a fantastic service! I've missed more trades than I care to remember. Doubled my money with you guys last week!
With your text alert I gained 40% on a trader friend. He waited on another service's email…
Just wanted you all to know that I got a premarket buy in today on your alert. Got out by 10AM with a cool $5K gain. Not bad.
Ja, FANTASTISCH! Ein Super Fahrvergnügen mit Stock Tipps! Danke! Danke! Danke!